[Translation] A single-arm, open-label, dose-escalation phase I clinical trial to evaluate the safety, tolerability, and pharmacokinetic characteristics of TR64 tablets in patients with advanced malignant solid tumors
主要研究目的:
评价 TR64 片在晚期恶性实体瘤患者的安全性和耐受性,确定最大耐受剂量,并评价TR64 片单药口服治疗的剂量限制性毒性(DLT),初步确定推荐的Ⅱ期临床试验剂量(RP2D)。
次要研究目的:
评价 TR64 片单次和多次给药在晚期恶性实体瘤患者的人体药代动力学特征。
探索性研究目的:
记录并初步评价TR64 片的抗肿瘤疗效(ORR、PFS、DOR、DCR 和CBR)。
[Translation] Main study objectives:
To evaluate the safety and tolerability of TR64 tablets in patients with advanced malignant solid tumors, determine the maximum tolerated dose, and evaluate the dose-limiting toxicity (DLT) of TR64 tablets for oral treatment alone, and preliminarily determine the recommended Phase II clinical trial dose (RP2D).
Secondary study objectives:
To evaluate the pharmacokinetic characteristics of single and multiple doses of TR64 tablets in patients with advanced malignant solid tumors.
Exploratory study objectives:
To record and preliminarily evaluate the anti-tumor efficacy (ORR, PFS, DOR, DCR and CBR) of TR64 tablets.